Sumitomo Chemical India Ltd Q2 FY2026 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/xsvn80pe22j4sw4ql6a0e0x4.pdf

Key Takeaways


Weather Impact & Demand Recovery

Chetan Shah: "I must admit that today, I was hoping to join you all with a very, very robust Q2 working on the basis of what we did in Q1. However, I think the God and the nature had some different plans of their own."

New Product Launches & Innovation Pipeline

Chetan Shah: "India has been put or Sumitomo Chemical India has been put by Japan as a #1 category for testing new molecules."

Manufacturing & Capex

Kunal Mittal: "We expect that during this current financial year, some of these projects should go and get approved both by our parent company and us and our Board. And once they get approved, we will take these projects to the implementation at the ground level, with implementation time lines of 18 months to 2 years. So maybe sometime in calendar year 2028, we see that some of these projects should start generating revenues."

Exports & Global Markets

Chetan Shah: "In spite of the very steep competition from China, due to our R&D efforts and process improvements, we have saved a lot of cost in order to compete with the Chinese prices. And I'm glad to inform that in all the products that we export as generic products, we are in a position to compete China."

Segment Performance

SegmentTrendCommentary
Domestic Crop Protection▼ Q2 hitKey brands Sumimax, Excalia Max, Lentigo and older herbicides gained traction despite weather; volume was the casualty, not brand strength.
Environmental Health▲ Healthy growthGrowing presence in branded solutions and urban vector control, off a low base.
Exports▬ MixedAfrica and LatAm deferred; US and Europe stable. H2 recovery expected as deferred shipments materialize.
Barrix Agro Sciences▬ Steady top lineRevenue broadly in line with previous year; profitability hit by higher input costs, elevated opex, and a regulatory disruption that blocked biostimulant sales from mid-June to late September.
Specialty vs Generic mix▲ Structural shiftSpecialty has grown from 22-24% of portfolio to 28-30% over five years. In H1 it dipped 1%, but management believes the structural growth trajectory remains intact.

Margins, Pricing & Financial Discipline

Chetan Shah: "The prices are definitely sustainable. As a matter of fact, if prices had to be lower, it was in this particular condition, a tough condition of Kharif. We have successfully maintained the price line even in these challenging months, I don't see any reason for us to lock the prices in the future."

Parent Company Relationship & Adjacent Opportunities

Chetan Shah: "Dealing with Japan as a country, it is very, very sustainable, but the speed can be lesser than what we expect it to be. So a little bit of delays or a little bit of this thing which we feel frustration about is due to the working style of Japan, basically, I would say that."

Guidance & Commitments

CommitmentSpecificsTimeline
Rabi demand recoveryCapitalize on healthy reservoir levels and improved field conditions to drive volume growthRabi season (H2 FY26)
Dahej project approvalsSome of the 7 projects to get parent and Board approval; 18-24 month implementation followsDuring current financial year (FY26)
Dahej revenue generationSome projects to start generating revenueCalendar year 2028
Excalia Max TG localizationPilot plant at Tarapur being completed; thereafter no need to import TG from JapanNot specified
Top Grain launchProduct from Valent BioSciences to launchH2 FY26
EBITDA marginMaintain or improve; will not go downOngoing
Cash deploymentFund Dahej capex; evaluate other opportunities; no return to shareholdersOngoing
Barrix sales restartLooking to start sales as soon as possible after regulatory disruptionNot specified

Key Metrics

MetricQ2 FY26
Revenue₹930 cr, down from ₹988 cr in Q2 FY25
H1 FY26 revenue₹1,987 cr, up 9% YoY from ₹1,827 cr
Gross margin43.1%, vs 42.6% in Q2 FY25
EBITDA₹218 cr, vs ₹245 cr in Q2 FY25
EBITDA margin23.4%, vs 24.8% in Q2 FY25
Profit after tax₹178 cr, vs ₹193 cr in Q2 FY25
PAT margin19.1%, vs 19.5% in Q2 FY25
H1 FY26 EBITDA margin22.0%, vs 22.2% in H1 FY25
H1 FY26 PAT₹356 cr, up 11% YoY
Domestic business growth (H1 FY26)11% YoY, contributing 85% of revenue
Export revenue growth (H1 FY26)-4% YoY; South America down 33%
Net working capital days55 days, improved by 7 days YoY
Cash and cash equivalents₹2,089 cr as of 30 Sep 2025
H1 FY26 collections~₹2,277 cr, vs ₹1,999 cr in H1 FY25
New product contribution8% to 10% of revenue on a yearly basis